The protective mechanism of docosahexaenoic acid in mouse model of Parkinson: The role of heme oxygenase

Özkan, Ayşe; Parlak, Hande; Tanrıöver, Gamze; Dilmaç, Sayra; Ülker, Seher Nasırcılar; Birsen, İlknur; Ağar, Ayşel

doi:10.1016/j.neuint.2016.10.012

Cited by 39 publications

(23 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Within LC‐PUFAs, DHA is the most important one for the brain; recently, in an experimental mouse model of PD the effects of the neurotoxin MPTP administrated together with DHA were evaluated. The results indicated that DHA has protective effects on dopaminergic neurons in this MPTP‐induced experimental model [124]. Transgenic animal models have also been used to test the protective effect of high levels of n‐3 PUFAs.…”

Section: Lipids and Neurodegenerative Disordersmentioning

confidence: 99%

Significance of long chain polyunsaturated fatty acids in human health

Zárate

Jaber-Vazdekis

Tejera

et al. 2017

Clinical & Translational Med

423

298

View full text Add to dashboard Cite

In the last decades, the development of new technologies applied to lipidomics has revitalized the analysis of lipid profile alterations and the understanding of the underlying molecular mechanisms of lipid metabolism, together with their involvement in the occurrence of human disease. Of particular interest is the study of omega-3 and omega-6 long chain polyunsaturated fatty acids (LC-PUFAs), notably EPA (eicosapentaenoic acid, 20:5n-3), DHA (docosahexaenoic acid, 22:6n-3), and ARA (arachidonic acid, 20:4n-6), and their transformation into bioactive lipid mediators. In this sense, new families of PUFA-derived lipid mediators, including resolvins derived from EPA and DHA, and protectins and maresins derived from DHA, are being increasingly investigated because of their active role in the “return to homeostasis” process and resolution of inflammation. Recent findings reviewed in the present study highlight that the omega-6 fatty acid ARA appears increased, and omega-3 EPA and DHA decreased in most cancer tissues compared to normal ones, and that increments in omega-3 LC-PUFAs consumption and an omega-6/omega-3 ratio of 2–4:1, are associated with a reduced risk of breast, prostate, colon and renal cancers. Along with their lipid-lowering properties, omega-3 LC-PUFAs also exert cardioprotective functions, such as reducing platelet aggregation and inflammation, and controlling the presence of DHA in our body, especially in our liver and brain, which is crucial for optimal brain functionality. Considering that DHA is the principal omega-3 FA in cortical gray matter, the importance of DHA intake and its derived lipid mediators have been recently reported in patients with major depressive and bipolar disorders, Alzheimer disease, Parkinson’s disease, and amyotrophic lateral sclerosis. The present study reviews the relationships between major diseases occurring today in the Western world and LC-PUFAs. More specifically this review focuses on the dietary omega-3 LC-PUFAs and the omega-6/omega-3 balance, in a wide range of inflammation disorders, including autoimmune diseases. This review suggests that the current recommendations of consumption and/or supplementation of omega-3 FAs are specific to particular groups of age and physiological status, and still need more fine tuning for overall human health and well being.

show abstract

Section: Lipids and Neurodegenerative Disordersmentioning

confidence: 99%

Significance of long chain polyunsaturated fatty acids in human health

Zárate

Jaber-Vazdekis

Tejera

et al. 2017

Clinical & Translational Med

423

298

View full text Add to dashboard Cite

show abstract

“…In mice, Nrf2 activity is strongly increased in the substantia nigra in response to Parkinson’s disease-related toxins including 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [ 24 , 52 , 53 , 54 ], 6-hydroxydopamine [ 55 ] or mutated α-synuclein [ 20 ], although rotenone decreases Nrf2 activity in rats [ 56 ]. Furthermore, exposing Nrf2 −/− mice to MPTP, 6-hydroxydopamine or α-synuclein causes more severe loss of dopaminergic neurons from substantia nigra and striatum compared to wild-type mice [ 24 , 54 , 57 , 58 , 59 ], clearly indicating the role of Nrf2 in dopaminergic neuronal survival.…”

Section: Parkinson’s Diseasementioning

confidence: 99%

Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration?

2017

View full text Add to dashboard Cite

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that regulates hundreds of antioxidant genes, and is activated in response to oxidative stress. Given that many neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease and multiple sclerosis are characterised by oxidative stress, Nrf2 is commonly activated in these diseases. Evidence demonstrates that Nrf2 activity is repressed in neurons in vitro, and only cultured astrocytes respond strongly to Nrf2 inducers, leading to the interpretation that Nrf2 signalling is largely restricted to astrocytes. However, Nrf2 activity can be observed in neurons in post-mortem brain tissue and animal models of disease. Thus this interpretation may be false, and a detailed analysis of the cell type expression of Nrf2 in neurodegenerative diseases is required. This review describes the evidence for Nrf2 activation in each cell type in prominent neurodegenerative diseases and normal aging in human brain and animal models of neurodegeneration, the response to pharmacological and genetic modulation of Nrf2, and clinical trials involving Nrf2-modifying drugs.

show abstract

“…In mouse models of PD, Nrf2 signalling in substantia nigra is also further elevated in response to MPTP (Chen et al, 2009;Ozkan et al, 2016;Swanson et al, 2013), 6hydroxydopamine (Jakel et al, 2005), and in the A53T α-synuclein model (Gan et al,…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

Nexus between mitochondrial function, iron, copper and glutathione in Parkinson's disease

Liddell

White

2018

Neurochemistry International

View full text Add to dashboard Cite

Parkinson's disease is neuropathologically characterised by loss of catecholamine neurons in vulnerable brain regions including substantia nigra pars compacta and locus coeruleus. This review discusses how the susceptibility of these regions is defined by their shared biochemical characteristics that differentiate them from other neurons. Parkinson's disease is biochemically characterised by mitochondrial dysfunction, accumulation of iron, diminished copper content and depleted glutathione levels in these regions. This review also discusses this neuropathology, and provides evidence for how these pathological features are mechanistically linked to each other. This leads to the conclusion that disruption of mitochondrial function, or iron, copper or glutathione metabolism in isolation provokes the pathological impairment of them all. This creates a vicious cycle that drives pathology leading to mitochondrial failure and neuronal cell death in vulnerable brain regions.

show abstract

The protective mechanism of docosahexaenoic acid in mouse model of Parkinson: The role of heme oxygenase

Cited by 39 publications

References 83 publications

Significance of long chain polyunsaturated fatty acids in human health

Significance of long chain polyunsaturated fatty acids in human health

Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration?

Nexus between mitochondrial function, iron, copper and glutathione in Parkinson's disease

Contact Info

Product

Resources

About